Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498990 | 0.92 | MEN1 (0.63) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL4491381 | 0.90 | LMNA (0.70) | KMT2AMEN1LMNACYP2D6 | |
| SCHEMBL4495526 | 0.84 | LMNA (0.68) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL4865941 | 0.83 | ABCB1 (0.61) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL4511466 | 0.82 | MEN1 (0.54) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL4865986 | 0.82 | KCNH2 (0.66) | LMNACYP2D6ABCB1 | |
| SCHEMBL4502993 | 0.81 | MEN1 (0.63) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL4496607 | 0.80 | LMNA (0.60) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL6284296 | 0.78 | CYP2D6 (0.64) | KMT2AMEN1ALDH1A1LMNACYP2D6 | |
| SCHEMBL4500396 | 0.78 | LMNA (0.55) | KMT2AMEN1ALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566717-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080275238-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | PALLE VENKATA | 2008-11-06 | — | — | US | disclosed |
| US-20070155728-A1 | Substituted Heterocyclic Compounds | PALLE VENKATA | 2007-07-05 | — | — | US | disclosed |
| US-7205303-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1578737-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040176356-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004063180-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176356-A1 | Substituted heterocyclic compounds | KCNH1, KCNJ2, SCN5A | KMT2A 2698/4885MEN1 4263/4885ALDH1A1 215/4885 |
| US-20080275238-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, SDHA, COQ8A | KMT2A 3029/4885MEN1 2899/4885ALDH1A1 281/4885 |
| US-20070155728-A1 | Substituted Heterocyclic Compounds | KCNH1, SDHA, COQ8A | KMT2A 3029/4885MEN1 2899/4885ALDH1A1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.